Journal of the Neurological Sciences
Volume 217, Issue 1 , Pages 31-35 , 15 January 2004

Neuron-specific enolase in patients with neurocysticercosis

  • José Eduardo Lima

      Affiliations

    • Department of Neurology, University of São Paulo School of Medicine at Ribeirão Preto, Ribeirão Preto, Campus Universitário, CEP 14048-900 São Paulo, Brazil
    • ,
  • Osvaldo Massaiti Takayanagui

      Affiliations

    • Department of Neurology, University of São Paulo School of Medicine at Ribeirão Preto, Ribeirão Preto, Campus Universitário, CEP 14048-900 São Paulo, Brazil
    • ,
  • Luis Vicente Garcia

      Affiliations

    • Department of Anesthesiology, University of São Paulo School of Medicine at Ribeirão Preto, São Paulo, Brazil
    • ,
  • João Pereira Leite

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +55-16-602-2556; fax: +55-16-633-0760.
    • Department of Neurology, University of São Paulo School of Medicine at Ribeirão Preto, Ribeirão Preto, Campus Universitário, CEP 14048-900 São Paulo, Brazil

Received 7 April 2003 ,Revised 30 June 2003 ,Accepted 12 August 2003.

References 

  1. Garcia HH, Evans CA, Nash TE, Takayanagui OM, White AC, Botero D, et al.  Current consensus guidelines for treatment of neurocysticercosis. Clin. Microbiol. Rev. 2002;15(4):747–756
  2. Roman G, Sotelo J, Del Brutto O, Flisser A, Dumas M, Wadia N, et al.  A proposal to declare neurocysticercosis an international reportable disease. Bull. World Health Organ. 2000;78(3):399–406
  3. Restrepo BI, Aguilar MI, Melby PC, Teale JM. Analysis of the peripheral immune response in patients with neurocysticercosis: evidence for T cell reactivity to parasite glycoprotein and vesicular fluid antigens. Am. J. Trop. Med. Hyg. 2001;65(4):366–370
  4. Grewal JS, Kaur S, Bhatti G, Sawhney IM, Ganguly NK, Mahajan RC, et al.  Cellular immune responses in human neurocysticercosis. Parasitol. Res. 2000;86(6):500–503
  5. White AC. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu. Rev. Med. 2000;51:187–206
  6. White AC. Neurocysticercosis: a major cause of neurological disease worldwide. Clin. Infect. Dis. 1997;24(2):101–113 [quiz 114–5]
  7. Fletcher L, Rider CC, Taylor CB. Enolase isoenzymes: III. Chromatographic and immunological characteristics of rat brain enolase. Biochim. Biophys. Acta. 1976;452(1):245–252
  8. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 1987;10:269–295
  9. Hay E, Royds JA, Davies-Jones GA, Lewtas NA, Timperley WR, Taylor CB. Cerebrospinal fluid enolase in stroke. J. Neurol. Neurosurg. Psychiatry. 1984;47(7):724–729
  10. Schaarschmidt H, Prange HW, Reiber H. Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke. 1994;25(3):558–565
  11. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 1999;30(6):1190–1195
  12. Fogel W, Krieger D, Veith M, Adams HP, Hund E, Storch-Hagenlocher B, et al.  Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit. Care Med. 1997;25(7):1133–1138
  13. Schoerkhuber W, Kittler H, Sterz F, Behringer W, Holzer M, Frossard M, et al.  Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Stroke. 1999;30(8):1598–1603
  14. DeGiorgio CM, Heck CN, Rabinowicz AL, Gott PS, Smith T, Correale J. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 1999;52(4):746–749
  15. Zerr I, Bodemer M, Racker S, Grosche S, Poser S, Kretzschmar HA, et al.  Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt–Jakob disease. Lancet. 1995;345(8965):1609–1610
  16. Kropp S, Zerr I, Schulz-Schaeffer WJ, Riedemann C, Bodemer M, Laske C, et al.  Increase of neuron-specific enolase in patients with Creutzfeldt–Jakob disease. Neurosci. Lett. 1999;261(1–2):124–126
  17. Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, et al.  Use of 14–3–3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt–Jakob disease. J. Neurol. Neurosurg. Psychiatry. 2001;70(6):744–748
  18. Aksamit AJ, Preissner CM, Homburger HA. Quantitation of 14–3–3 and neuron-specific enolase proteins in CSF in Creutzfeldt–Jakob disease. Neurology. 2001;57(4):728–730
  19. Studahl M, Rosengren L, Gunther G, Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J. Neurol. 2000;247(8):636–642
  20. Del Brutto OH, Rajshekhar V, White AC, Tsang VC, Nash TE, Takayanagui OM, et al.  Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57(2):177–183
  21. Carpio A, Placencia M, Santillan F, Escobar A. A proposal for classification of neurocysticercosis. Can. J. Neurol. Sci. 1994;21(1):43–47
  22. Sterk M, Oenings A, Eymann E, Roos W. Development of a new automated enzyme immunoassay for the determination of neuron-specific enolase. Anticancer Res. 1999;19(4A):2759–2762
  23. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders: II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand. J. Clin. Lab. Invest. 1977;37(5):391–396
  24. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders: I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 1977;37(5):385–390
  25. Webbe G. Human cysticercosis: parasitology, pathology, clinical manifestations and available treatment. Pharmacol. Ther. 1994;64(1):175–200
  26. Agapejev S. Epidemiology of neurocysticercosis in Brazil. Rev. Inst. Med. Trop. Sao Paulo. 1996;38(3):207–216
  27. Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N. Engl. J. Med. 1992;327(10):696–701
  28. Royds JA, Timperley WR, Taylor CB. Levels of enolase and other enzymes in the cerebrospinal fluid as indices of pathological change. J. Neurol. Neurosurg. Psychiatry. 1981;44(12):1129–1135
  29. Hardemark HG, Ericsson N, Kotwica Z, Rundstrom G, Mendel-Hartvig I, Olsson Y, et al.  S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J. Neurosurg. 1989;71(5 Pt. 1):727–731
  30. Cunningham RT, Young IS, Winder J, O'Kane MJ, McKinstry S, Johnston CF, et al.  Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur. J. Clin. Investig. 1991;21(5):497–500
  31. Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, et al.  Serum neurone-specific enolase as an indicator of stroke volume. Eur. J. Clin. Investig. 1996;26(4):298–303
  32. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997;28(10):1956–1960
  33. Del Brutto OH. Single parenchymal brain cysticercus in the acute encephalitic phase: definition of a distinct form of neurocysticercosis with a benign prognosis. J. Neurol. Neurosurg. Psychiatry. 1995;58(2):247–249
  34. Sciutto E, Fragoso G, Fleury A, Laclette JP, Sotelo J, Aluja A, et al.  Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Microbes Infect. 2000;2(15):1875–1890
  35. Carpio A. Neurocysticercosis: an update. Lancet, Infect. Dis. 2002;2(12):751–762
  36. Monteiro L, Lopes J, Martins da Silva A. Relationship between cysticercosis and epilepsy. Epilepsia. 1999;40(10):1464–1465
  37. Leite JP, Terra-Bustamante VC, Fernandes RM, Santos AC, Chimelli L, Sakamoto AC, et al.  Calcified neurocysticercotic lesions and postsurgery seizure control in temporal lobe epilepsy. Neurology. 2000;55(10):1485–1491

PII: S0022-510X(03)00255-7

doi: 10.1016/j.jns.2003.08.008

Journal of the Neurological Sciences
Volume 217, Issue 1 , Pages 31-35 , 15 January 2004

Article Tools